Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Wenbin Jiang is PRESIDENT AND CEO at Cytek Biosciences. OQRO lists 12 transactions filed with the SEC under this name, the latest on Nov 20, 2026, each linked to the official Form 4.
PRESIDENT AND CEO
Disclosures on record
12
Companies involved
1
Cytek BiosciencesCTKB
12 disclosures · Nov 2026
Nov 18, 202657Kdisclosed Nov 20
DetailsOfficial recordNov 18, 202612Kdisclosed Nov 20
DetailsOfficial recordNov 18, 202622Kdisclosed Nov 20
DetailsOfficial recordNov 18, 202629Kdisclosed Nov 20
DetailsOfficial recordNov 18, 202612Kdisclosed Nov 20
DetailsOfficial recordNov 18, 202622Kdisclosed Nov 20
DetailsOfficial recordNov 18, 202629Kdisclosed Nov 20
DetailsOfficial recordNov 18, 202657Kdisclosed Nov 20
DetailsOfficial recordNov 18, 20264,636disclosed Nov 20
DetailsOfficial recordNov 18, 202611Kdisclosed Nov 20
DetailsOfficial recordNov 18, 20268,697disclosed Nov 20
DetailsOfficial recordNov 18, 202623Kdisclosed Nov 20
DetailsOfficial recordWenbin Jiang has no open-market purchase on record since 2022. Sales in 2 of the 5 years since 2022.
Wenbin Jiang reported 0 open-market purchases and 23 sales since 2022; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2023 | — | $1.93M11×11 trades |
| 2022 | — | $2.74M12×12 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Wenbin Jiang reported 0 open-market purchases and 23 sales here, 2022 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
As of the latest filing on , Wenbin Jiang reported holding 5,633,865 shares of Cytek Biosciences (CTKB), worth about $34.5M at the last close of $6 (Nov 20, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Cytek Biosciences CTKB | 5,633,865 | 5.63M direct | $6 | $34.5M | Nov 18, 2026 |
Is this Wenbin Jiang’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 18, 2026, Wenbin Jiang reported holding 5,633,865 shares of Cytek Biosciences (CTKB). At the last close of $6 on Nov 20, 2026, that is about $34.5M. This is the stake disclosed in filings, not a net worth.
No public filing gives Wenbin Jiang's net worth. What SEC Form 4 shows is the stock stake: 5,633,865 shares of Cytek Biosciences (CTKB), about $34.5M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Wenbin Jiang has no open-market purchase on record since 2022. Sales in 2 of the 5 years since 2022.
In SEC filings since 2022: no open-market purchase is on record; the latest open-market sale is from 2023.
Cytek Biosciences (CTKB), from 2022 to 2023: 0 purchases and 23 sales.